Acumen Pharmaceuticals
ABOS
80 hedge funds and large institutions have $73.2M invested in Acumen Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 28 increasing their positions, 19 reducing their positions, and 8 closing their positions.
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
47% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 19
10% more funds holding
Funds holding: 73 → 80 (+7)
1.79% less ownership
Funds ownership: 72.58% → 70.79% (-1.8%)
32% less capital invested
Capital invested by funds: $108M → $73.2M (-$34.5M)
68% less call options, than puts
Call options by funds: $64K | Put options by funds: $201K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$2.11M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$286K |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$227K |
| 4 |
Pathstone Holdings
Englewood,
New Jersey
|
+$216K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$192K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.01M |
| 2 |
Millennium Management
New York
|
-$1.18M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.11M |
| 4 |
Jane Street
New York
|
-$1.1M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$663K |
ABOS Hedge Fund Activity: Q4 2024 in Review
80 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q4 2024, worth a combined $73.2M — down 32% from $108M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ABOS positions and 8 closed out — a net gain of 8 holders — while 28 added to existing stakes and 19 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $2.11M. The largest seller was T. Rowe Price Associates, cutting an estimated $2.01M.
- 80 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q4 2024, up from 73 in Q3 2024.
- Funds reported $73.2M of Acumen Pharmaceuticals stock for Q4 2024, down 32% quarter-over-quarter.
- 16 funds opened new Acumen Pharmaceuticals positions in Q4 2024 and 8 closed out, a net change of +8 holders.
- The largest Acumen Pharmaceuticals buyer in Q4 2024 was JP Morgan Chase, an estimated $2.11M added.
- The largest Acumen Pharmaceuticals seller in Q4 2024 was T. Rowe Price Associates, an estimated $2.01M sold.
Based on aggregated 13F filings for Q4 2024.